Core Viewpoint - The domestic high-performance silicon photomultiplier (SiPM) has achieved significant breakthroughs in localization, marking a successful end to foreign monopolies in this field [1][2]. Group 1: Company Achievements - China General Nuclear Power Corporation's subsidiary, CGN Technology Development Co., Ltd., has successfully established a SiPM packaging production line with a device yield exceeding 90% [2]. - The successful production line fills the gap in domestic high-performance SiPM products, providing strong support for the stability of the industrial chain [4]. - The production line has passed EU RoHS certification and is on track to obtain ISO certification, laying a solid foundation for large-scale application and market expansion [4]. Group 2: Market Potential and Applications - SiPMs are widely used in advanced fields such as nuclear medical imaging, nuclear measurement and control equipment, high-energy physics research, and biological sciences due to their high sensitivity, low noise, and low power consumption [4]. - The domestic SiPM market has long been dominated by foreign companies, and achieving self-control of core components has been included in national development plans [4]. Group 3: Future Plans and Strategies - The company aims to continuously optimize and enhance SiPM product performance based on market demand and customer feedback, focusing on building core competitiveness [6]. - CGN Technology Development Co., Ltd. is committed to becoming a leader in the non-power nuclear technology application industry and is exploring new models for mixed-ownership development [7].

Core Insights - Significant breakthrough in the domestic production of high-performance Silicon Photomultiplier (SiPM) in China, marking the end of foreign monopoly in this sector [1] - The successful establishment of the SiPM packaging production line by China General Nuclear Power Corporation (CGN) and its subsidiary, CGN Beijing Institute of Optoelectronics Technology, achieving over 90% yield rate [1] Group 1 - SiPM is a core optoelectronic conversion device with advantages such as high sensitivity, low noise, and low power consumption, widely used in nuclear medical imaging, nuclear measurement and control equipment, high-energy physics research, and biological sciences [1] - The domestic SiPM market has been dominated by foreign companies until now, highlighting the importance of this development for national security and technological independence [1] Group 2 - The company invested in building a high-standard cleanroom with a cleanliness level of up to 100, and designed a high-level packaging production line that integrates standardized production and quality control [2] - Future plans include optimizing SiPM product performance based on market demand and customer feedback, while focusing on market expansion in relevant fields to enhance core competitiveness and ensure the resilience and safety of the industrial chain [2]

Group 1 - The concept stocks related to nuclear pollution prevention have seen a significant rise, with Jihua Group hitting the daily limit up [1] - China Nuclear Technology previously reached the daily limit up, indicating strong market interest [1] - Other companies such as Jieqiang Equipment and China General Nuclear Power Technology have increased by over 5% [1] Group 2 - Additional stocks that experienced gains include Sandam Membrane, China Electric Environmental Protection, Construction Repair, and Beihua Co., Ltd [1]

Group 1 - The nuclear pollution prevention concept sector saw a rise of 4.35%, ranking second among concept sectors, with 36 stocks increasing in value [1][2] - Notable stocks that hit the 20% limit up include Hengguang Co., Jiekang Equipment, and Zhongjin Irradiation, while stocks like Hanwei Technology and Yingliu Co. experienced declines [1][2] - The sector attracted a net inflow of 1.26 billion yuan from main funds, with 33 stocks receiving net inflows, and 14 stocks exceeding 50 million yuan in net inflows [2][3] Group 2 - The top three stocks by net inflow ratio were Jiekang Equipment (31.53%), Jihua Group (26.72%), and Zhongguang Nuclear Technology (24.36%) [3] - The leading stocks in the nuclear pollution prevention concept based on net inflow included Jihua Group, Beihua Co., and Zhongguang Nuclear Technology, with net inflows of 174 million yuan, 151 million yuan, and 140 million yuan respectively [2][3] - The overall trading performance of the sector was strong, with several stocks showing significant increases in turnover rates and net inflow ratios [3][4]

Group 1 - The nuclear pollution prevention sector has seen significant gains, with companies like China General Nuclear Power Technology (000881) reaching the daily limit increase [1] - Other companies in the sector, such as Jieqiang Equipment (300875), Beihua Co., Ltd. (002246), and Huashengchang (002980), also experienced a surge, hitting their daily limit [1] - Zhongjin Irradiation (300962) rose nearly 19%, indicating strong market interest in nuclear-related stocks [1] Group 2 - Additional companies like China Electric Environmental Protection (300172), Rongji Software (002474), and others also followed the upward trend, reflecting a broader market movement in this sector [1] - The overall positive sentiment in the nuclear pollution prevention sector suggests potential investment opportunities as more companies join the rally [1]

Core Viewpoint - The proton medical business of China General Nuclear Power Technology Development Co., Ltd. (CGN Tech) has received support from its controlling shareholder, which is expected to facilitate the development of this business segment [2][4]. Group 1: Investment and Financial Support - The controlling shareholder, China General Nuclear Technology Application Co., Ltd., plans to inject 500 million yuan into CGN Tech's wholly-owned subsidiary, CGN Medical Technology (Mianyang) Co., Ltd., to support the research and development of proton medical projects [2]. - After the capital increase, the controlling shareholder will hold 44.13% of the shares in Mianyang Medical, while CGN Tech's shareholding will decrease to 55.87%, transforming Mianyang Medical from a wholly-owned subsidiary to a controlled subsidiary [4]. Group 2: Business Development and Market Potential - CGN Tech's medical health business began in 2020, focusing on the introduction of multi-room proton therapy technology from Belgium's IBA and establishing a manufacturing base for proton medical equipment in Mianyang, Sichuan [2]. - Proton therapy is recognized for its high precision, low side effects, and shorter treatment duration, making it increasingly popular among doctors and patients [3]. - The company has made significant progress in its proton medical business, including the development of a compact proton therapy system with independent intellectual property rights and the completion of its proton industry park, which has commenced production [3][4]. Group 3: Industry Insights - The demand for proton medical equipment is expected to grow due to increasing health awareness and advancements in medical technology, indicating a broad development space for this sector [3]. - The cash injection from the controlling shareholder is anticipated to alleviate financial pressure on CGN Tech and enhance its core competitiveness in the medical health business [5].

Group 1 - The company held its 28th meeting of the 10th Board of Directors on June 6, 2025, with all 9 directors present [2][3] - The board approved the strategic project for proton medical treatment [4] - The board also approved a capital increase of 500 million RMB from the controlling shareholder to its wholly-owned subsidiary, CGN Medical Technology (Mianyang) Co., Ltd [5][21] Group 2 - The capital increase will allow the subsidiary to develop proton medical technology and will maintain the subsidiary's status as a controlled entity of the company [21][34] - The board's decision on the capital increase was made with the avoidance of related directors, ensuring compliance with regulations [22][61] - The company plans to hold its 2024 annual shareholders' meeting on June 30, 2025 [41][42] Group 3 - The company approved revisions to its articles of association and management regulations during the board meeting [10][13] - The independent directors unanimously agreed that the transaction pricing was fair and would not affect the company's independence [36][61] - The company has had previous related transactions amounting to 37.88 million RMB with its controlling shareholder in 2025 [37]

中广核核技术发展股份有限公司 股东会议事规则 第一章 总则 第一条 为规范中广核核技术发展股份有限公司（以下简称"公司"）行为， 保证公司股东会依法行使职权，根据《中华人民共和国公司法》（以下简称《" 公 司法》"）《中华人民共和国证券法》（以下简称《证券法》）《上市公司章程指引（2025 年修订）》《上市公司股东会规则》、《深圳证券交易所股票上市规则（2025 年修 订）》《深圳证券交易所上市公司自律监管指引第 1 号－－主板上市公司规范运作》 （以下简称《规范运作指引》）及其他有关法律、法规和《中广核核技术发展股 份有限公司公司章程》（以下简称"公司章程"）的规定，制定本规则。 第二条 公司股东会的召集、提案、通知、召开等事项适用本规则。 第三条 公司应当严格按照法律、行政法规、本规则及公司章程的相关规定 召开股东会，保证股东能够依法行使权利。 公司董事会应当切实履行职责，认真、按时组织股东会。公司全体董事应当 勤勉尽责，确保股东会正常召开和依法行使职权。 第四条 股东会应当在《公司法》和公司章程规定的范围内行使职权。 第五条 股东会分为年度股东会和临时股东会。年度股东会每年召开一次， 应当于上一会计年度 ...

Group 1 - The core point of the announcement is the approval of a capital increase by the controlling shareholder, China General Nuclear Power Corporation, to its wholly-owned subsidiary, China General Nuclear Medical Technology (Mianyang) Co., Ltd., amounting to 500 million yuan, which is seen as beneficial for the company's nuclear medical business development [1][2] - The supervisory board held a meeting on June 5, 2025, where the decision regarding the capital increase was made, with all members present either in person or via remote voting [1] - The resolution regarding the capital increase was passed with a unanimous vote of 3 in favor, with no votes against or abstentions, and it will be submitted for approval at the 2024 annual shareholders' meeting [1] Group 2 - The supervisory board also approved amendments to the company's articles of association, which will also be submitted for approval at the 2024 annual shareholders' meeting [2] - The announcement emphasizes that the related party transaction was conducted fairly and reasonably, ensuring no harm to the company or its shareholders, particularly minority and non-related shareholders [1]

中广核核技术发展股份有限公司 股东会议事规则 第第第 第第 第第第 第第第第第第第第第第第第第第第第第第第第第第"第第"第第第第第第第第第第第第第第第第第第第 第第第第第第第第第第第第第第第第第第"第第第第第"第第第第第第第第第第第第第第第第第第第第 第第第第第第第第第第第第第第2025第第第第第第第第第第第第第第第第第第第第第第第第第第第 第第第第第2025第第第第第第第第第第第第第第第第第第第第第第第第1第第第第第第第第第第第第 第第第第第第第第第第第第第第第第第第第第第第第第第第第第第第第第第第第第第第第第第第第第 第第第第第第第第"第第第第"第第第第第第第第第第第 第二条 公司股东会的召集、提案、通知、召开等事项适用本规则。 | 三 | 第 | 第 | | --- | --- | --- | | 第第第第第第第第第第第第第第第第第第第第第第第第第第第第第第第第第第第第第第第第第第第第 | | | 第第第第 第第第第第第第第第第第第第第第第第第第第第第第第第第第第第第第第第第第第第第第第第第 第第第第第第第第第第第第第 第四第 第第第第第第第第第第第第第第第第第第第第第第第第第第第 第 五 第 第第第第 ...